Bristol-Myers Squibb (BRM) Stock Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details

BRM fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	4/6
Financial Health	3/6
Dividends	5/6

Rewards

Trading at 49.2% below our estimate of its fair value

Earnings grew by 83.8% over the past year

Pays a reliable dividend of 3.89%

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 6.9% per year for the next 3 years

Large one-off items impacting financial results

Has a high level of debt

Last Earnings Call

Q2 2026 · 30 Jul 2026

Full Transcript

Bristol-Myers Squibb (BMS) reported a strong Q2 2026, with revenue of $13 billion, a 5% year-over-year increase. The growth portfolio—featuring key assets like Reblozyl, Breyanzi, and Camzyos—rose 14%, now accounting for nearly 60% of total revenue. Eliquis remained a standout, with 21% growth. Due to this first-half momentum, management raised full-year 2026 revenue and adjusted EPS guidance.

Analyst Consensus vs. Actual Results:

Revenue: Consensus estimates were approximately $12.75 billion. BMS beat expectations with $13 billion.
Adjusted EPS: Consensus estimates were $1.98. BMS beat expectations with $2.04.

Management emphasized continued investment in its CELMoD platform (iberdomide, mezigdomide) and highlighted progress in its pipeline, though they noted timing updates for milvexian and the Cobenfy ADEPT program, now expected to read out in 2027.

Market Reaction

Bristol-Myers Squibb’s stock rose by approximately 3.2% on July 30, 2026. Analysts cited the earnings beat, the raised full-year financial guidance, and the robust 14% growth in the company's core "growth portfolio" as primary drivers for the positive investor sentiment.

BRM Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW478,504 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

478,504 investors already sharing narratives

View all narratives

Bristol-Myers Squibb Company Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bristol-Myers Squibb
Historical stock prices
Current Share Price	US$55.41
52 Week High	US$60.64
52 Week Low	US$36.65
Beta	0.23
1 Month Change	10.64%
3 Month Change	17.74%
1 Year Change	41.71%
3 Year Change	-1.23%
5 Year Change	-3.10%
Change since IPO	21.31%

Recent updates

Shareholder Returns

	BRM	DE Pharmaceuticals	DE Market
7D	-2.2%	1.7%	2.2%
1Y	41.7%	52.6%	3.5%

Return vs Industry: BRM underperformed the German Pharmaceuticals industry which returned 52.6% over the past year.

Return vs Market: BRM exceeded the German Market which returned 3.5% over the past year.

Price Volatility

Is BRM's price volatile compared to industry and market?
BRM volatility
BRM Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	5.3%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: BRM has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: BRM's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1887	32,500	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM.

Bristol-Myers Squibb Company Fundamentals Summary

How do Bristol-Myers Squibb's earnings and revenue compare to its market cap?
BRM fundamental statistics
Market cap	€114.33b
Earnings (TTM)	€8.03b
Revenue (TTM)	€42.54b

14.2x

P/E Ratio

2.7x

P/S Ratio

Is BRM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BRM income statement (TTM)
Revenue	US$49.19b
Cost of Revenue	US$13.94b
Gross Profit	US$35.25b
Other Expenses	US$25.97b
Earnings	US$9.28b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Oct 29, 2026

Earnings per share (EPS)	4.54
Gross Margin	71.66%
Net Profit Margin	18.87%
Debt/Equity Ratio	193.2%

How did BRM perform over the long term?

See historical performance and comparison

Dividends

3.9%

Current Dividend Yield

55%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/09 12:46
End of Day Share Price	2026/08/07 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bristol-Myers Squibb Company is covered by 45 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Emily Field	Barclays
Charles Butler	Barclays

Bristol-Myers Squibb (BRM) Stock Overview

Rewards

Risk Analysis

Market Reaction

Join community and earn perks

Bristol-Myers Squibb Company Competitors

Merck KGaA

Dermapharm Holding

GSK

Sanofi

Price History & Performance

Recent News & Updates

AstraZeneca And Bristol Myers Squibb Reportedly Engages In Merger Talks

Second quarter 2026 earnings released: EPS: US$1.62 (vs US$0.64 in 2Q 2025)

Bristol Myers Squibb Receives FDA Acceptance for New Drug Application For Mezigdomide in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 3000E Growth Benchmark

First quarter dividend of US$0.63 announced

Bristol Myers Squibb Declares Quarterly Dividend, Payable on August 3, 2026

Recent updates

AstraZeneca And Bristol Myers Squibb Reportedly Engages In Merger Talks

Second quarter 2026 earnings released: EPS: US$1.62 (vs US$0.64 in 2Q 2025)

Bristol Myers Squibb Receives FDA Acceptance for New Drug Application For Mezigdomide in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 3000E Growth Benchmark

First quarter dividend of US$0.63 announced

Bristol Myers Squibb Declares Quarterly Dividend, Payable on August 3, 2026

Bristol Myers Squibb Announces A Supplemental New Drug Application

Bristol-Myers Squibb Company Presents Positive Phase 3 Results For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Bristol Myers Squibb Unveils New Data Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

Bristol Myers Squibb Launch Sotyktu Approaches to Tyk2 Adoption

Insufficient new directors

Bristol Myers Squibb Receives European Commission Approval of Sotyktu for the Treatment of Active Psoriatic Arthritis in Adults

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Announces Data from Phase 4 Clinical Trial Evaluating Symptom Stability, Safety and Tolerability of Cobenfy (Xanomeline and Trospium Chloride)

Bristol-Myers Squibb Company, Annual General Meeting, May 05, 2026

Bristol Myers Squibb Presents New Camzyos Data At American College of Cardiology Annual Scientific Session & Expo 2026

Bristol Myers Squibb announces Opdivo (nivolumab) received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and the European Union

Evotec Se Receives Milestone for Initiation of Clinical Study of Bms-986506 in Collaboration with Bristol Myers Squibb

Bristol-Myers Squibb Company to Report Q1, 2026 Results on Apr 30, 2026

Bristol Myers Squibb Announces Positive Phase 3 Results From Successor-2 Study Of Oral Mezigdomide In Relapsed Or Refractory Multiple Myeloma

Bristol Myers Squibb Receives U.S. FDA Approval For Sotyktu For Treatment Of Adults With Active Psoriatic Arthritis

Bristol Myers Squibb Declares Quarterly Dividend, Payable on May 1, 2026

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha-Thalassemia

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

Piramal Critical Care B.V. entered into an agreement to acquire Kenalog Brand of Bristol-Myers Squibb Company (NYSE:BMY) for $100 million.

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (Mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Amgen Inc. (NasdaqGS:AMGN) acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company (NYSE:BMY) and Evotec SE (XTRA:EVT) in a transaction valued at $840 million.

Bristol-Myers Squibb Company to Report Q4, 2025 Results on Feb 05, 2026

Bristol Myers Squibb Announces Dividend Increase, Payable on February 2, 2026

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

Bristol Myers Squibb's Breyanzi Approves by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Bristol Myers Squibb Announces Continuation of Adept-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

Bristol Myers Squibb Data At Ash 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

State of Texas Sues Bristol-Myers Squibb and Sanofi for Deceptive Marketing of Blood Thinner Plavix

Bristol Myers Squibb in Collaboration with Johnson & Johnson Announces Update on Phase 3 Librexia ACS Trial

Bristol-Myers Squibb Company Updates Earnings Guidance for the Year 2025

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (Deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-Bren, an EGFR X HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors At ESMO 2025

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Orbital Therapeutics, Inc. for $1.5 billion.

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-To-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib)

Bristol-Myers Squibb Company Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company to Report Q3, 2025 Results on Oct 30, 2025

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on November 3, 2025

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (Mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Systimmune Inc. and Bristol Myers Squibb Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Systimmune Inc

Bristol Myers Squibb's Application for Breyanzi (Lisocabtagene Maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Bristol Myers Squibb Announces Management Changes

Bristol Myers Squibb's Supplemental New Drug Application for Sotyktu (Deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 1000 Defensive Index

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on August 1, 2025

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo®? (nivolumab) Across Multiple Solid Tumor Indications

Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo®? (Nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with Pd-1 Expression 1%

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT).

Bristol Myers Squibb Announces Executive Changes